Every quarter Lumida Wealth presents a visual summary of the 45+ hedge funds we track every quarter that shape the future investing trends.
Enjoy the visual summary below or Check out the full data along with Ram’s insights in spreadsheet format here.
Please note:
– AUM indicates assets under management in managed 13F securities only, the overall AUM due to other positions (Debt, options etc) may be higher.
– Color intensity indicates relative weight.
– Individual stock Rectangles optimized for mobile readability and are not to scale
– Percentages are rounded to nearest decimal and indicate current portfolio weights
– We have prioritized top 5 stock positions wherever available.
– Each manager has a summary, sector analysis and legend for stock information.
Compliance Disclaimer: The information is for general informational purposes only and does not constitute investment advice. Past performance is not indicative of future results, and investments in hedge funds carry risks, including the potential loss of principal. We recommend that you seek independent financial advice before making any investment decisions.
Data Sources: Hedgefollow, Whalewisdom, Lumida analysis
Summary Overview
Perceptive Advisors, led by Joseph Edelman, is heavily focused on the healthcare sector, particularly in biotechnology and pharmaceuticals. The fund’s top holdings include significant investments in companies developing innovative therapies, while recent activity shows new investments in emerging biotech firms, alongside reductions in existing biotech positions.
3 sector-specific insights
- The top holdings reflect a strong emphasis on biotechnology, with major investments in companies like Cerevel Therapeutics and Amicus Therapeutics.
- New investments in emerging biotech firms suggest a strategic interest in innovative therapies and cutting-edge research.
- Reductions in existing biotech holdings indicate a rebalancing or profit-taking strategy.
Top 5 holdings, additions, and reduced positions
- NUVL (Nuvalent, Inc.): Healthcare sector, focuses on creating precisely targeted therapies for patients with cancer.
- IOVA (Iovance Biotherapeutics, Inc.): Healthcare sector, develops novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology.
- ACLX (Arcellx, Inc.): Healthcare sector, develops cell therapies for cancer treatment.
- FOLD (Amicus Therapeutics, Inc.): Healthcare sector, focuses on developing therapies for rare and orphan diseases.
- CERE (Cerevel Therapeutics Holdings, Inc.): Healthcare sector, develops therapies for neuroscience diseases.
New Holdings
- CGEM (Cullinan Oncology, Inc.): Healthcare sector, focuses on developing a diversified pipeline of targeted oncology and immuno-oncology therapies.
- INBX (Inhibrx, Inc.): Healthcare sector, develops protein-based therapeutics for the treatment of cancer and other diseases.
- RAPP (RAPT Therapeutics, Inc.): Healthcare sector, focuses on developing oral small molecules for oncology and inflammatory diseases.
- MRUS (Merus N.V.): Healthcare sector, develops bispecific antibody therapeutics for cancer treatment.
- CTNM (Centessa Pharmaceuticals plc): Healthcare sector, focuses on developing medicines that address unmet needs across a range of diseases.
Reduced Holdings
- MDGL (Madrigal Pharmaceuticals, Inc.): Healthcare sector, focuses on the development of novel therapeutics for cardiovascular, metabolic, and liver diseases.
- NBIX (Neurocrine Biosciences, Inc.): Healthcare sector, develops treatments for neurological and endocrine-related diseases and disorders.
- PCVX (Vaxcyte, Inc.): Healthcare sector, focuses on developing vaccines to prevent or treat infectious diseases.
- NUVL (Nuvalent, Inc.): Healthcare sector, focuses on creating precisely targeted therapies for patients with cancer.
- ACLX (Arcellx, Inc.): Healthcare sector, develops cell therapies for cancer treatment.
